查尔斯河实验室(CRL)最主要的收入来源是什么？

通过最新财报数据拆解，该公司的收入主要由其核心业务板块与相关服务支持构成。您可以通过页面上的交互式图表直观查看各业务线对总营收的具体贡献比例。

如何直观分析 CRL 的财务状况与盈利模式？

瓜壳日历通过交互式桑基图(Sankey Diagram)和瀑布图(Waterfall Chart)，将该公司的总营收、销售成本、运营费用以及最终的净利润流程进行了全景可视化，方便投资者一分钟看懂其经营效率与现金流走向。

Income Statement Q1 2026
Item	Category	Value	YoY
Total revenue	revenue	995.83M	1.18%
Income (loss) before income taxes	profit	29.94M	-16.78%
Interest income	revenue	1.03M	-26.42%
Operating income (loss)	profit	119.90M	60.57%
Cost of revenue (excluding amortization of intangible assets)	cost	608.91M	5.45%
Selling, general and administrative	cost	159.42M	-10.34%
Amortization of intangible assets	cost	15.35M	-76.49%
Aggregate	revenue	150.87M	98.33%
Other (expense) income, net	revenue	124.13M	916.54%
Interest expense, nonoperating	cost	26.74M	-4.10%

Business Breakdown
Segment	Value	YoY
Discovery and Safety Assessment	596.92M	0.73%
Research Models and Services	208.37M	-2.21%
Manufacturing Support	190.54M	6.75%

Products Breakdown
Segment	Value	YoY
Service	798.15M	0.03%
Product	197.68M	6.14%

Balance Sheet Q1 2026
Item	Category	Value
Trade receivables and contract assets, net of allowances for credit losses of $8,114 and $10,463, respectively	assets	700.25M
Inventories	assets	359.72M
Cash and cash equivalents	assets	191.83M
Other current assets	assets	134.86M
Prepaid assets	assets	102.15M
Total current assets	assets	1.49B
Goodwill	assets	3.04B
Property, plant and equipment, net	assets	1.51B
Other assets	assets	826.16M
Operating lease right-of-use assets, net	assets	317.84M
Intangible assets, net	assets	248.99M
Venture capital and strategic equity investments	assets	209.72M
Deferred tax assets	assets	88.60M
Total assets	assets	7.73B
Total liabilities	liabilities	4.74B
Total equity	liabilities	2.95B
Redeemable noncontrolling interests	liabilities	41.90M
Long-term debt, net and finance leases	liabilities	2.66B
Total current liabilities	liabilities	1.09B
Other long-term liabilities	liabilities	510.65M
Operating lease right-of-use liabilities	liabilities	393.11M
Deferred income tax liabilities, net	liabilities	81.40M
Nonredeemable noncontrolling interest	liabilities	5.82M
Treasury stock, common, value	equity	209.99M
Accumulated other comprehensive loss	equity	191.04M
Total charles river laboratories international, inc. equity	equity	2.94B
Accrued liabilities	liabilities	372.40M
Other current liabilities	liabilities	226.14M
Deferred revenue	liabilities	194.33M
Accrued compensation	liabilities	166.89M
Accounts payable	liabilities	133.95M
Aggregate	equity	3.34B
Additional paid-in capital	equity	1.97B
Retained earnings	equity	1.37B
Common stock, value, issued	equity	493000

Operating Activities – 3M 2026
Item	Value
Gain (loss) on disposition of business	117.98M
Depreciation and amortization	67.15M
Increase (decrease) in inventories	26.00M
Stock-based compensation	22.38M
Accounts payable	20.45M
Long-lived asset impairments	15.86M
Deferred revenue	5.20M
Write down of inventories	1.49M
Venture capital and equity method investments, gain (loss) and impairments, net	1.14M
Provision for credit losses	47000
Customer contract deposits	-135000
Increase (decrease) in other operating assets and liabilities, net	-8.52M
Net income (loss)	-14.80M
Deferred income taxes	-29.42M
Other noncash income (expense)	-34.67M
Increase (decrease) in accounts receivable	-65.32M
Accrued compensation	-83.76M

Investing Activities – 3M 2026
Item	Value
Proceeds from sale of businesses and assets, net	60.10M
Proceeds from sale of investments	2.92M
Payment for (proceeds from) other investing activity	-1.46M
Payments to acquire investments	-8.49M
Capital expenditures	-55.91M
Payments to acquire businesses, net of cash acquired	-405.01M

Financing Activities – 3M 2026
Item	Value
Proceeds from long-term debt and revolving credit facility	912.46M
Proceeds from exercises of stock options	1.22M
Other, net	-2.00M
Payments for repurchase of common stock	-208.28M
Repayment of long-term debt, long-term lease obligation, and capital security	-355.68M

Cash Balance – 3M 2026
Item	Value
Cash and cash equivalents, beginning of period	216.00M
Cash and cash equivalents, end of period	198.20M